{"groups":[{"description":"Nivolumab 3 mg/kg was administered as a 60 minute IV infusion Q2W","id":"FG000","title":"Nivolumab 3 mg/kg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"167"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"31"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"39"}],"type":"Adverse Event Unrelated to Study Drug"},{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Participant Request to Discontinue Treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Subject Withdrew Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Poor/Non-Compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Other Reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"270"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"comment":"Completed=continuing in the study treatment","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"270"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}